文献速递消化道肿瘤与早癌消化内镜

基于粪便免疫化学检测的结直肠癌筛查在发现早期病变中的有效性——丹麦全国性队列研究

Effectiveness of Colorectal Cancer Screening in Detecting Earlier-Stage Disease-A Nationwide Cohort Study in Denmark.
PubMed 文献 · Gastroenterology · 2018-04-05

该研究基于丹麦登记数据库的回顾性队列,在2014年3月1日至2015年6月30日筛查流行期首16个月内,比较受邀与尚未受邀接受粪便免疫化学检测(FIT)筛查者的结直肠癌(CRC)发病率与分期。受邀者CRC发病率为339.4/10万,尚未受邀者为169.6/10万;受邀女性I期CRC的RR为3.39(95%CI 2.61-4.39),受邀男性I期CRC的RR为3.71(95%CI 2.97-4.64)。结论认为邀请个体接受FIT筛查使CRC检出增加近2倍。

要点

  • 受邀筛查者CRC发病率为339.4/10万,尚未受邀者为169.6/10万。
  • 受邀女性I期CRC的RR为3.39(95%CI 2.61-4.39),IV期RR为0.92(95%CI 0.68-1.23)。
  • 受邀男性I期CRC的RR为3.71(95%CI 2.97-4.64),IV期RR为1.20(95%CI 0.95-1.52)。

核心结论

  • 邀请个体接受基于FIT的CRC筛查使CRC检出例数较未邀请者增加近2倍,受邀者CRC发病率显著增加提示引入FIT筛查的国家需关注治疗能力。

研究设计与样本

  • 基于登记数据库的回顾性队列研究,收集FIT结直肠癌筛查项目流行期首16个月(2014年3月1日至2015年6月30日)数据。
  • 402,826名50-72岁丹麦居民在研究期内被随机邀请接受CRC筛查,956,514名在此后被邀请。
  • 从丹麦结直肠癌组数据库获取CRC诊断、日期和分期信息,计算每10万受邀/尚未受邀者的癌症发病率及受邀者相对尚未受邀者的相对风险(RR)。

主要发现

  • 研究期间CRC发病率在受邀者为339.4/10万,在尚未受邀者为169.6/10万。
  • 受邀者和尚未受邀者的CRC发病率均随年龄增加。
  • 受邀女性相比尚未受邀女性,I期CRC的RR为3.39(95%CI 2.61-4.39),II期RR为2.16(95%CI 1.71-2.72),III期RR为1.37(95%CI 1.08-1.75),IV期RR为0.92(95%CI 0.68-1.23)。
  • 受邀男性相比尚未受邀男性,I期CRC的RR为3.71(95%CI 2.97-4.64),II期RR为2.26(95%CI 1.84-2.77),III期RR为1.88(95%CI 1.53-2.30),IV期RR为1.20(95%CI 0.95-1.52)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Most studies of the effectiveness of screening for colorectal cancer (CRC) using the fecal occult blood test tested the guaiac fecal occult blood test. However, the fecal immunochemical test (FIT) is now commonly used in screening. We aimed to evaluate the effectiveness of FIT-based screening for CRC on the number of incident CRC diagnoses and stage at diagnosis for individuals in Denmark who were invited for screening vs not yet invited. METHODS: We collected data for this register-based retrospective cohort study during the first 16 months of the prevalence round of a FIT-based CRC screening program (March 1, 2014 through June 30, 2015). A total of 402,826 residents of Denmark (50-72 years old) were randomly invited to undergo CRC screening within the study period, and 956,514 were invited thereafter. We obtained information on CRC diagnosis, date, and stage at diagnosis from the Danish Colorectal Cancer Group database. Cancer incidence per 100,000 invited/not yet invited individuals was calculated, along with the relative risk (RR) of CRC among invited compared with not yet invited individuals. RESULTS: CRC incidence during the study period was 339.4/100,000 invited individuals and 169.6/100,000 not yet invited individuals. CRC incidence increased with age among invited and not yet invited individuals. For invited women compared with not yet invited women, the RR of being diagnosed with stage I CRC was 3.39 (95% CI, 2.61-4.39), with stage II CRC was 2.16 (95% CI, 1.71-2.72), with stage III CRC was 1.37 (95% CI, 1.08-1.75), and with stage IV CRC was 0.92 (95% CI, 0.68-1.23). For invited men compared with not yet invited men, the RR of being diagnosed with stage I CRC was 3.71 (95% CI, 2.97-4.64); with stage II CRC was 2.26 (95% CI, 1.84-2.77), with stage III CRC was 1.88 (95% CI, 1.53-2.30), and with stage IV CRC was 1.20 (95% CI, 0.95-1.52). CONCLUSIONS: In analyzing data from a register-based cohort study in Denmark, we found that inviting individuals to undergo FIT-based CRC screening led to detection of almost 2-fold more cases of CRC than not inviting participants. The significant increase of CRC incidence among those invited for screening indicates a need for awareness of treatment capacity in countries introducing FIT-based CRC screening.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Larsen MB, Njor S, Ingeholm P, et al. Effectiveness of Colorectal Cancer Screening in Detecting Earlier-Stage Disease-A Nationwide Cohort Study in Denmark. Gastroenterology. 2018. PMID: 29626451. doi:10.1053/j.gastro.2018.03.062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。